Contingency Management for the Treatment of Methamphetamine Use Disorders

Roll, John M.; Petry, Nancy M.; Stitzer, Maxine L.; Brecht, Mary Lynn; Peirce, Jessica M.; McCann, Michael; Blaine, Jack; MacDonald, Benjamin; DiMaria, R.N. Joan; Lucero, Leroy; Kellogg, Scott

doi:10.1176/ajp.2006.163.11.1993

Cited by 132 publications

(84 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…from MA use, a contingency management (behavioral reinforcement) intervention was provided (Roll et al, 2006). Non-cash vouchers for goods and services promoting a healthy drug-free lifestyle were earned for MA metabolite-free urine samples, on an escalating schedule for the first 4 weeks after signing consent, then remaining at this level for the remaining 10 weeks prior to discontinuation.…”

Section: Contingency Management-to Increase the Likelihood Of Initiatmentioning

confidence: 99%

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Shoptaw

Heinzerling

Rotheram-Fuller

et al. 2008

Drug and Alcohol Dependence

138

129

View full text Add to dashboard Cite

Objective-To compare bupropion to placebo for reducing methamphetamine (MA) use, increasing retention, and reducing the severity of depressive symptoms and MA cravings. A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants.Methods-Following a 2-week, non-medication baseline screening period, 73 treatment-seeking MA dependent participants were randomly assigned to bupropion sustained release (150 mg twice daily; N=36) or placebo (twice daily; N=37) for 12-weeks under double blind conditions. Participants attended clinic thrice weekly to provide urine samples analyzed for MA-metabolite, to complete research measures and assessments, and to receive contingency management and weekly cognitive behavioral therapy sessions.Results-There were no statistically significant effects for bupropion relative to placebo on MA use verified by urine drug screens, for reducing the severity of depressive symptoms or MA cravings, or on study retention. In a post hoc analysis, there was a statistically significant effect of bupropion treatment on MA use among participants with lighter (0-2 MA-positive urines), but not heavier (3-6 MA-positive urines) MA use during baseline (OR=2.81, 95% CI=1.61-4.93, p<0.001 for MA-free week with bupropion among light users). Bupropion treatment was also associated with significantly reduced cigarette smoking, by almost 5 cigarettes per day (p=0.0002).Conclusion-Bupropion was no more effective than placebo in reducing MA use in planned analyses, though bupropion did reduce cigarette smoking. Post hoc findings of an effect for bupropion among baseline light, but not heavy, MA users suggests further evaluation of bupropion for light MA users is warranted.

show abstract

Section: Contingency Management-to Increase the Likelihood Of Initiatmentioning

confidence: 99%

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Shoptaw

Heinzerling

Rotheram-Fuller

et al. 2008

Drug and Alcohol Dependence

138

129

View full text Add to dashboard Cite

show abstract

“…Several studies have documented a high posttreatment rate of relapse among MA-dependent individuals, showing that the benefits of treatment quickly diminish within the postdischarge period, starting as early as 3 months (Brecht et al, 2005(Brecht et al, , 2008Brecht and Herbeck, 2014;Gonzales et al, 2010;Hser et al, 2003Hser et al, , 2005Rawson et al, 2002Rawson et al, , 2004Roll et al, 2006). Consequently, there is considerable interest in identifying interventions that can help reduce relapse to MA use, particularly among subgroups of MA-dependent users.…”

Section: Introductionmentioning

confidence: 99%

Impact of an exercise intervention on methamphetamine use outcomes post residential treatment care

Rawson

Chudzynski

Gonzales-Castaneda

et al. 2015

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background-We examined the efficacy of an 8-week exercise intervention on posttreatment methamphetamine (MA) use among MA-dependent individuals following residential treatment.Methods-135 individuals newly enrolled in treatment were randomly assigned to a structured 8-week exercise intervention or health education control group. Approximately 1 week after completion of the intervention, participants were discharged to the community. Interview data and urine samples were collected at 1-, 3-, and 6-months post-residential care. Of the sample, 54.8% were classified as higher severity users (using MA more than 18 days in the month before admission) and 45.2% as lower severity users (using MA for up to 18 days in the month before admission). Group differences in MA use outcomes were examined over the 3 timepoints using mixed-multivariate modeling.Results-While fewer exercise participants returned to MA use compared to education participants at 1-, 3-and 6-months post-discharge, differences were not statistically significant. A significant interaction for self-reported MA use and MA urine drug test results by condition and MA severity was found: lower severity users in the exercise group reported using MA significantly fewer days at the three post-discharge timepoints than lower severity users in the ContributorsAuthors RAR, LM, and CBC were involved with the design the study. Authors RG, JC, BAS managed literature searches and summaries of previous related work. Authors JP, DD, and BD undertook behavioral and clinical data collection. AA and RG undertook the statistical analysis. All authors contributed to the writing of the manuscript, including the review and final approval of it for publication. Conflicts of interest: none.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript education group. Lower severity users in the exercise group also had a lower percentage of positive urine results at the three timepoints than lower severity users in the education group. These relationships were not present in the comparison of the higher severity conditions. Conclusion-Resultssupport the value of exercise as a treatment component for individuals using MA 18 or fewer days/month.

show abstract

“…These costs include premature mortality, crime and lost productivity, environmental damage and medical conditions such as cardiovascular insults, cognitive dysfunction, and infectious disease (Pasic et al 2007;Shoptaw et al 2009). Behavioral treatments like contingency management and cognitivebehavioral therapy effectively reduce methamphetamine use (Lee and Rawson 2008;Roll et al 2006;Shoptaw et al 2006;Smout et al 2010). However, many patients enrolled in behavioral treatment programs are unable to achieve significant periods of abstinence suggesting other strategies like pharmacotherapy are needed.…”

Section: Introductionmentioning

confidence: 99%

Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance

et al. 2010

View full text Add to dashboard Cite

Rationale Methamphetamine abuse and dependence are significant public-health concerns. Behavioral therapies are effective for reducing methamphetamine use. However, many patients enrolled in behavioral therapies are unable to achieve significant periods of abstinence, suggesting other strategies like pharmacotherapy are needed. Objectives This experiment determined the subjective and physiological effects of intranasal methamphetamine during D-amphetamine maintenance in eight non-treatment-seeking stimulant-dependent participants. We predicted D-amphetamine maintenance would attenuate the acute subjective effects of intranasal methamphetamine. We also predicted intranasal methamphetamine would be well tolerated during D-amphetamine maintenance. Methods After at least 7 days of maintenance on sustainedrelease D-amphetamine (0 and 45 mg/day), participants were administered ascending doses of intranasal methamphetamine (0, 2.5, 5, 10, and 20 mg) across two experimental sessions. Intranasal methamphetamine doses were separated by 90 min. Results Intranasal methamphetamine produced prototypical subjective and physiological effects (e.g., increased ratings of Like Drug; increased heart rate, blood pressure, and body temperature). The acute effects of intranasal methamphetamine were significantly diminished during D-amphetamine maintenance relative to placebo maintenance. Conclusions These results are concordant with those of clinical trials and provide further support for the use of agonist replacement therapy to manage methamphetamine dependence. Additional research in humans is needed to determine the effectiveness of D-amphetamine under different experimental conditions that more closely reflect use in the natural environment (e.g., higher methamphetamine doses) and behavioral arrangements that are predictive of pharmacotherapy effectiveness (e.g., drug self-administration).

show abstract

Contingency Management for the Treatment of Methamphetamine Use Disorders

Abstract: These results suggest that contingency management has promise as a component in treatment strategies for methamphetamine use disorder.

Cited by 132 publications

References 47 publications

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Impact of an exercise intervention on methamphetamine use outcomes post residential treatment care

Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance

Contact Info

Product

Resources

About